You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》美銀證券下調阿里健康(00241.HK)目標價至23元 評級「買入」
阿思達克 08-18 15:21
美銀證券發表的研究報告指,阿里健康(00241.HK)旗下Dr. Deer應用程式流量勢頭理想,7月份月活躍用戶增至275萬戶,而每名月活躍用戶平均每月使用時間增至11分鐘,認為應用程式可助用戶跟蹤本地新冠疫情消息,尋找疫苗中心及預約新冠測試服務,因此估計新一波疫情將帶動流量提升,而阿里健康亦推出了外展護士服務,助年長用戶在家獲得醫療服務。公司的直營業務包括是建立疾病護理中心,例如是夥德國製藥公司Boehringer-Ingelheim建立柏金遜症中心,另外亦與羅氏(Roche)合作建立流感專科中心等。 該行維持對公司2022財年收入預測不變,料將為230億元人民幣,按年增49%,但就將2022上半財年收入預測降至100億元人民幣,按年升39%,下半財年預測升至130億元人民幣,按年升57%,主要考慮上半年基數較下半年具挑戰。另外該行料2022財年首季公司將有30%至40%的增長,主要受惠處方藥錄三位數升幅,但就將2022財年全年利潤預測下調,以反映公司新業務投資。將公司目標價由28元降至23元,評級「買入」,認為公司應受惠行業數碼化趨勢。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account